Enveric Biosciences Inc. (ENVB)
0.35
-0.02 (-4.63%)
At close: Jan 15, 2025, 12:26 PM
Company Description
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care.
Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy.
Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Enveric Biosciences Inc.
| Country | United States |
| IPO Date | May 4, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Dr. Joseph Edward Tucker Ph.D. |
Contact Details
Address: 4851 Tamiami Trail North Naples, Florida United States | |
| Website | https://www.enveric.com |
Stock Details
| Ticker Symbol | ENVB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000890821 |
| CUSIP Number | 29405E208 |
| ISIN Number | US29405E2081 |
| Employer ID | 95-4484725 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Joseph Edward Tucker Ph.D. | Chief Executive Officer & Director |
| Kevin M. Coveney CPA | Chief Financial Officer |
| Dr. Peter J. Facchini Ph.D. | Chief Innovation Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 14, 2025 | S-1 | Filing |
| Jan 06, 2025 | SCHEDULE 13G | Filing |
| Jan 03, 2025 | 8-K | Current Report |
| Dec 18, 2024 | DEF 14A | Filing |
| Dec 12, 2024 | PRER14A | Filing |
| Nov 27, 2024 | PRE 14A | Filing |
| Nov 22, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |